The use of small animal models as surrogates for humans in the study of normal and disease states has a long history. The models used have ranged from the simplest possible to those as complex as the investigator’s imagination and skills allow. Growing opportunities to apply methods of molecular and cellular biology to the study and treatment of human disease have increased demand for the creation of animal models with more humanlike diseases. Cultures of cancer cells growing in vitro, or as tumors on the flank of a small animal, no longer suffice because treatment agents and techniques that enjoy even great success in such milieus too frequently prove to be utter failures in phase I testing in humans. These failures propel investigators to understand disease, and its progression and treatment, by better means than observations of less-faithful models, such as a growing cell line. They see more fruitful approaches in molecular and cellular manipulations of animals to model the whole disease process more faithfully. Successful creations of live, whole animals that more faithfully model human diseases led to an obvious desire for a way to image disease progression in each animal, without resort to biopsy or sacrifice to answer every question. Most early animal imaging studies used instruments and techniques designed for human use, during hours when this equipment was not in clinical use. However, systems optimized for human use frequently yield suboptimal results for small animal studies. In addition, there are other problems associated with mixing animal and patient studies on clinical instruments. The growing need for dedicated small animal imaging systems was noticed by the Biomedical Imaging Program of the National Cancer Institute (NCI) and was included among other issues explored in series of workshops held to better define the needs for cancer imaging and areas in which special NCI initiatives might provide the most impetus for change and advancement. One subgroup addressing small animal imaging—the In vivo Molecular/Functional Imaging Subgroup (MIS), chaired by Elias Zerhouni, MD—recommended that the National Institutes of Health (NIH) and NCI should support dedicated small animal imaging facilities focusing on the study of genetically engineered tumor models (http://cancer.gov/bip/ISWG3.htm). They also recommended that the greater part of the efforts of the facilities be directed toward imaging, not the creation of new instruments. Workshop participants concluded that the facilities should provide imaging by more than one technique because they did not like the prospect of limiting the range of scientific questions open to investigation by having only one modality at hand. With this workshop recommendation in mind, the Biomedical Imaging Program developed a concept for Small Animal Imaging Resource Project (SAIRP) grants, which the May 1998 NCI Board of Scientific Advisors approved enthusiastically. The concept was for the Biomedical Imaging Program to budget support for approximately four SAIRPs under the R24 mechanism, which specifies the development of research resource centers. Each grantee would be expected to provide access to at least two different imaging modalities and serve at least six funded cancer research projects by the end of the 2nd year of operation. The Biomedical Imaging Program translated the concept into a request for applications, set a receipt date of November 1998, and defined the objectives and scope as follows: (a) multiple imaging technologies for small animals, emphasizing, but not limited to those technologies that can provide biochemical, genetic or Acad Radiol 2001; 8:372–374
Read full abstract